Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Yuhan Corporation
A recent event in South Korea heard one prominent investor advise South Korean pharma firms to sharply increase their new drug R&D and seek direct entry into global markets, rather than pursuing licensing deals for growth
Through its latest government-linked project, Korean pharma consortium Kimco aims to speed up industry collaboration and step up technology competitiveness to move into rapidly growing pharmerging markets.
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.
- Generic Drugs
- Drug Discovery Tools
- Other Names / Subsidiaries
- Yuhan USA